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1. Introduction 
Small for gestational age (SGA) is defined as a birth weight and/or birth length below -2 
standard deviation scores (SDS), adjusted for gestational age (Clayton et al., 2007). To 
determine whether a child is born SGA, accurate knowledge of gestational age, accurate 
measurements of weight and length at birth, and an appropriate reference population to 
calculate the standard deviation scores are required.  The child can be further subclassified 
as SGA for weight, SGA for height or SGA for height and weight. 
SGA only refers to size at birth and does not take fetal growth into account. The term 
intrauterine growth retardation (IUGR) is used when the fetus suffers from reduced fetal 
growth, based on at least 2 subsequent ultrasound measurements. A child born SGA has not 
necessarily suffered from IUGR, whereas a child with IUGR late in gestation can have a 
normal size at birth. These different fetal growth patterns are shown in Figure 1. 
 
 
Fig. 1. Fetal growth chart demonstrating various growth curves in SGA and IUGR 
newborns. LGA=large for gestational age, AGA=appropriate for gestational age, SGA=small 
for gestational age, IUGR=intrauterine growth retardation. 
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1.1 Prevalence and etiology of SGA 
By definition, 2.3% of all live-born neonates are born SGA when SGA is defined as a birth 
weight and/or length below -2 SDS.  Intrauterine growth retardation might be caused by 
numerous fetal, maternal, placental and environmental factors which are outlined in Table 
1. The cause of IUGR remains, however, unidentified in 40% of the children. 
 
Fetal factors  
Multiple births  
Congenital malformations  
Chromosomal anomalies Turner syndrome 
Down syndrome 
Inborn errors of metabolism  
Intrauterine infections Toxoplasmosis, Other infections, Rubella, 
Cytomegalovirus, Herpes simplex (TORCH) 
Maternal factors  
Medical conditions Pre-eclampsia 
Acute or chronic hypertension 
Severe chronic disease 
Severe chronic infections 
Systemic lupus erythematosus 
Antiphospholipid syndrome 
Anemia 
Malignancy 
Abnormalities of the uterus 
Social conditions Malnutrition 
Low prepregnancy body mass index 
Low maternal weight gain 
Delivery at age < 16 or > 35 years 
Low socioeconomic status 
Drug use (smoking, alcohol, illicit drugs) 
Placental factors  
Reduced blood flow  
Reduced area for exchange of 
oxygen and nutrients 
Infarcts 
Hematomas 
Partial abruption 
Environmental factors  
Toxic substances  
High altitude  
Table 1. Factors associated with intrauterine growth retardation. Adapted from Bryan and 
Hindmarsh (Bryan & Hindmarsh, 2006). 
2. GH-IGF-IGFBP axis 
Fetal and postnatal growth and development are regulated by metabolic and endocrine 
processes, which are influenced by genetic and environmental factors. The Growth 
Hormone – Insulin-like Growth Factor – Insulin-like Growth Factor Binding Protein (GH-
IGF-IGFBP) axis plays a major role in this system (Figure 2). 
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Growth hormone is secreted by the pituitary gland under the control of the hypothalamic 
hormones growth hormone releasing hormone (GHRH), somatostatin and ghrelin. The 
major effects of growth hormone on growth are mediated via Insulin-like Growth Factor I 
(IGF-I) expression. The physiological actions of growth hormone involve longitudinal 
bone growth and bone remodeling, skeletal muscle growth and immunomodulation 
(Holt, 2002).  
The IGF-family consists of insulin, IGF-I and IGF-II. The metabolic actions of insulin are 
mediated through binding to the insulin receptor. The growth-promoting effects of IGF-I 
and IGF-II are primarily mediated through binding to the IGF-I receptor. Interactions 
between IGFs and the insulin receptor exist, because of strong homology between IGFs and 
insulin, and between the insulin receptor and IGF-I receptor (Steele-Perkins et al., 1988). 
Between 0.4% and 2% of IGF-I circulates as free or very easily dissociable IGF-I, the main 
biological active fraction. The physiological actions of IGFs involve growth, development 
and function of the central nervous system, skeletal muscle and reproductive organs. 
 
 
Fig. 2. Physiology of the GH-IGF-IGFPB axis (Holt, 2002). 
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Six IGF binding proteins (IGFBPs) form complexes with IGF-I and IGF-II, ensuring that 
more than 95% of IGF-I is bound. The majority of IGF-I and IGF-II (75%) is bound in a 
ternary complex with IGFBP-3 and an acid-labile subunit (ALS). IGFBP-3 is mainly 
produced in the liver. The concentration of IGFBP-3 in serum exceeds that of other IGFBPs 
and the affinity of IGFBP-3 for IGFs is higher than those of most other IGFBPs, reflecting its 
most important function as a carrier protein for IGFs. In vitro and in vivo studies have 
demonstrated that IGFBP-3 has IGF-mediated as well as IGF-independent effects on growth 
promotion and inhibition (Collet-Solberg & Cohen, 2000; Conover et al., 1996). 
2.1 Genes involved in the GH-IGF-IGFBP axis 
2.1.1 Growth hormone and growth hormone receptor gene 
Common polymorphisms have small effects on a phenotype, but can provide important 
contributions to understanding complex diseases. Single nucleotide polymorphisms in the 
growth hormone gene have been associated with variability in normal adult height (Esteban 
et al., 2007). A common polymorphism in the growth hormone receptor gene (growth 
hormone receptor d3 polymorphism) was associated with size at birth and response to 
growth hormone treatment in some cohorts, although these findings were not reproduced 
by others (Carrascosa et al., 2006; de Graaff et al., 2008; Tauber et al., 2007). 
Laron syndrome is caused by inactivating mutations affecting the expression or function of 
the growth hormone receptor. Clinical characteristics include severe postnatal growth 
failure, facial dysmorphism, truncal obesity, delayed puberty, hypoglycemia, elevated 
growth hormone levels, low IGF-I levels, absent/low or dysfunctional growth hormone 
binding protein (GHBP) and resistance to growth hormone (Laron et al., 1966). 
2.1.2 IGF and IGF receptor genes 
Animal knockout studies have demonstrated that IGF-I, IGF-II and their receptors are 
important regulators of fetoplacental growth. IGF-I gene knockout mice are 40% smaller 
than their littermates, without an alteration in placental size, whereas IGF-II gene knockout 
mice are also 40% smaller and have reduced placental growth. IGF-I gene receptor knockout 
mice are the most severely growth retarded (45% of normal birth weight) because of the loss 
of both IGF-I and IGF-II action (Baker et al., 1993). Liver IGF-I deficient mice, a mouse model 
where the IGF-I gene is specifically knocked out in the liver, have a normal birth weight and 
postnatal growth despite reduced circulating IGF-I and IGFBP3 levels. These data show that, 
at least in mice, liver-derived IGF-I is not essential for postnatal growth and development 
(Yakar et al., 1999). 
Case reports in humans with defects in the IGF-I gene or IGF-I receptor gene 
demonstrated variable pre- and postnatal growth retardation as well as mental 
retardation in some cases (de Lacerda et al., 1999; Ester et al., 2009a; Veenma et al., 2010, 
Walenkamp et al., 2005). 
Twin studies have shown that 40-65% of interindividual variability in IGF-I, IGF-II and 
IGFBP-3 levels is genetically determined (Harrela et al., 1996). Single nucleotide 
polymorphisms in the IGF-I gene are correlated with IGF-I levels, head circumference in 
short SGA children, birth weight and increased risk of type 2 diabetes and ischemic heart 
disease, although not all studies found similar associations (Ester et al., 2009b; Frayling et 
al., 2002; Johnston et al., 2003; Vaessen et al., 2001).  
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2.1.3 IGFBP genes 
Knockout studies of genes encoding for IGFBPs or the acid-labile subunit demonstrated 
little effect on fetal growth. Knockout of the ALS gene resulted in a 60% reduction in IGF-I 
and IGFBP-3 levels, without an effect on fetal growth, only minor effects on postnatal 
growth and no effects on glucose metabolism, questioning the role of circulating IGF-I levels 
versus local autocrine-paracrine production of IGF-I (Ueki et al., 2000). Polymorphic 
variation in the IGFBP-3 gene promoter region is associated with IGFBP-3 levels, 
spontaneous growth and response to growth hormone treatment in short children born SGA 
(van der Kaay et al., 2009a).  
3. The GH-IGF-IGFBP axis in fetal and postnatal growth 
3.1 Fetal growth 
Infants with congenital absence of the pituitary often have birth weights and birth lengths 
below the mean, although within the normal range, demonstrating that pituitary growth 
hormone has limited impact on late third trimester growth (Gluckman et al., 1992). 
Fetal growth is determined by adequate delivery of oxygen and nutrients, in particular 
glucose, amino acids and lactate or ketone bodies across the placenta. Insulin, IGF-I and 
IGF-II and their receptors are the most important regulators of fetoplacental growth. IGF-II 
is the main growth factor in early embryonic growth, whereas IGF-I is more important 
during later stages of gestation. IGF-I and IGF-II levels are significantly influenced by the 
availability of adequate glucose levels. Glucose increases IGF-I levels through an increase in 
insulin secretion. In fetuses with intrauterine growth retardation, IGF-I levels are decreased 
during the second half of gestation. Cord blood IGF-I levels are significantly lower in infants 
born small for gestational age, compared to infants born appropriate for gestational age 
(Giudice et al., 1995; Gluckman et al., 1987).  
All 6 IGFBPs have been found in fetal plasma and tissues. IGFBP-1 is the major IGF binding 
protein found in amniotic fluid. It binds IGF in fetal plasma, increases 20-fold from week 9 
to week 12 and is the most important regulator of IGF-I bioavailability during pregnancy 
(Murphy et al., 2006). IGFBP-1 production is suppressed by insulin. IGFBP-1 levels are 
increased in infants born SGA, possibly reflecting the low insulin levels found in fetuses 
with intrauterine growth retardation (Holt, 2002). IGFBP-3 levels are significantly lower in 
infants born small for gestational age, compared to those born appropriate for gestational 
age (Giudice et al., 1995). 
3.2 Postnatal growth 
Growth hormone receptor expression is gradually upregulated after birth. Around 6 months 
of life, growth becomes dependent on pulsatile growth hormone secretion and growth 
hormone induced IGF-I and IGFBP-3 production. Serum IGF-I and IGFBP-3 levels are 
influenced by various factors such as sex steroids, nutritional status and liver function. 
Catch-up growth is defined as a growth velocity greater than the median for chronological 
age and gender and is associated with a rise in IGF-I and IGFBP-3 levels (Cance-Rouzaud et 
al., 1998). In infants born SGA, catch-up growth occurs during the first 6 months of life in 
more than 80% of children. Prematurely born infants may take longer to catch-up (Hokken-
Koelega et al., 1995). Catch-up growth is completed by the age of 2 years in most children 
born SGA (Figure 3). 
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Fig. 3. Percentage of pre-term and full-term SGA infants with postnatal catch-up growth 
(Hokken-Koelega et al., 1995). 
It is recommended that a child born SGA has measurements of height, weight, and head 
circumference every 3 months for the first year of life and every 6 months thereafter. 
Children without significant catch-up growth in the first 6 months of life and those who 
remain short by 2 years of age may have other conditions that are associated with short 
stature. These children require referral to a pediatrician because such conditions need to be 
identified and managed (Clayton et al., 2007). 
Although catch-up growth occurs in most children born SGA, around 10% of infants remain 
short throughout childhood and adulthood (Leger et al., 1997). Alterations in the GH-IGF-
IGFBP axis might underlie this failure in catch-up growth in short SGA children. Subnormal 
to low growth hormone levels during overnight growth hormone profiles have been found 
in prepubertal short SGA children in some cohorts, although others found normal growth 
hormone levels (Boguszewski et al., 1995; de Waal et al., 1994; Volkl et al., 2004). The wide 
variability in – and overlap between – growth hormone secretion in SGA cohorts and 
control populations are consistent phenomena. Within the heterogeneous SGA population, 
this probably reflects a continuum in growth hormone secretion, ranging from partial 
growth hormone deficiency to normal growth hormone secretion. 
IGF-I and IGFBP-3 levels are significantly lower in short prepubertal and pubertal children, 
and young adults who were born SGA, compared to their age-matched peers with normal 
stature (de Waal et al., 1994; Carel et al., 2003; Verkauskiene et al., 2005). 
4. Short children born small for gestational age 
4.1 Metabolic status of short children born SGA 
Body composition is greatly influenced by gender and height. It is important to adjust for 
these variables when comparing body composition in short SGA children and controls. 
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Prepubertal short SGA children have a significantly decreased fat mass. Lean body mass is 
comparable to controls in young prepubertal short SGA children. During a 3-year follow-up, 
however, it tended to decrease over time resulting in significantly lower levels in older 
prepubertal short SGA children compared to controls (Willemsen et al., 2007). 
Epidemiological studies have demonstrated that development of type 2 diabetes mellitus and 
associated disorders such as hypertension, dyslipidemia and cardiovascular disease in adults 
is associated with low birth weight (Barker, 2004; Barker et al., 2005). Reduced insulin 
sensitivity plays a central role in the pathogenesis of these disorders. Short children born SGA 
are more insulin resistant, compared to controls born appropriate for gestational age. The 
disposition index – reflecting the capability of beta cells to compensate for the reduction in 
insulin sensitivity by increasing their insulin secretion – was comparable between short SGA 
subjects and controls (Leunissen et al., 2008). Young adults born SGA have a higher incidence 
of metabolic risk factors than those born appropriate for gestational age (2.3% versus 0.4%). 
More recent data indicate that insulin resistance and metabolic risk factors are mainly related 
to the accumulation of fat mass during early childhood. Rapid weight gain during the first 3 
months of life results in a higher percentage of body fat, more central adiposity, reduced 
insulin sensitivity, lower high-density lipoprotein cholesterol levels and higher triglyceride 
levels in early adulthood (Arends et al., 2005; Jaquet et al., 2005; Leunissen et al., 2009). High 
blood pressure in childhood has been associated with an increased risk of developing 
hypertension in adulthood (Bao et al., 1995; Primatesta et al., 2005). 
4.2 Intellectual consequences and health-related quality of life of short children born 
SGA 
In large observational studies, cognitive impairment is independently associated with low 
birth weight, short birth length, and small head circumference. SGA children have poorer 
school performance and have more emotional, conduct, and attention deficit hyperactivity 
disorders, although the differences are mostly subtle (de Bie et al., 2010; van Pareren et al., 
2004).  
Adults who were born SGA show no difference in frequency of employment, marital status, 
or satisfaction with life. However, lower academic achievement and professional attainment 
with lower income have been found (Strauss, 2010).  
Short children have reported to experience juvenilization and more teasing. Reports on 
health-related quality of life, the subjective perception of health, have been inconclusive 
(Sandberg & Colsman, 2005). More recently, a large British population study found that 
adult short stature may be associated with a reduction in health-related quality of life on 
five dimensions (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression) (Christensen et al., 2007). 
5. Growth hormone treatment in prepubertal short children born SGA 
5.1 Effects on linear growth 
Growth hormone treatment in short children born SGA has been explored for over 40 years. 
Several studies have demonstrated that growth hormone treatment effectively induces 
catch-up growth in prepubertal short SGA children (Dahlgren & Wikland, 2005; de Zegher 
et al., 2006; Sas et al., 1999). Adult height data from a Dutch multicenter study demonstrated 
that 85% of children reached a height above -2 SDS and 98% reached a height within the 
target height range (Van Pareren et al., 2003) (Figure 4). 
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Fig. 4. Height SDS (± SD) during growth hormone treatment and at adult height (AH), in 
relation to target height (TH) SDS. Light blue boxes: 1 mg GH/m2/day, dark blue boxes: 2 
mg GH/m2/day (Van Pareren et al., 2003). 
This has led to the official registration of GH treatment for short children born SGA by the 
US Food and Drug Administration (FDA) in 2001 and by the European Agency for the 
Evaluation of Medicinal Products (EMEA) in 2003 (Table 2). 
Discrepancies, for example in height at start of treatment and dose, between the 2 approved 
indications are recognized (Chernausek, 2005). A dose-dependent effect on growth is found 
during the first 4-5 years of growth hormone treatment, although growth hormone dose is 
less important for long-term growth (de Zegher & Hokken-Koelega, 2005; Van Pareren et al., 
2003). Furthermore, there is no evidence for excluding children from growth hormone 
treatment when the distance to target height is less than 1 SDS (Lem et al., 2010). 
There is considerable variation in the growth response to growth hormone treatment. This 
variation remains after adjustment for factors such as age, target height and duration of 
treatment. Short children born SGA form a heterogeneous group of patients and genetic 
variability in growth-related genes probably accounts for part of the variation in growth 
response. 
A positive response to GH treatment could arbitrarily be defined as a height velocity SDS of 
more than 0.5 in the first year of treatment. In case of an inadequate response, reevaluation 
is necessary, including consideration of compliance, GH dose, diagnosis, and the decision to 
discontinue treatment. Discontinuation of GH treatment in adolescence is recommended 
when the growth rate is less than 2 cm/yr (Clayton et al., 2007). 
5.2 Effects on the GH-IGF-IGFBP axis 
Serum growth hormone, IGF-I and IGFBP-3 levels significantly increase in a dose-dependent 
manner during growth hormone treatment (Boguszewski et al., 1996; Sas et al., 1999; Van Dijk 
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et al., 2006). During 1 year of treatment, IGF-I and IGFBP3 levels had increased to respectively 
+1.2 SDS and +0.2 SDS in children treated with 1 mg GH/m2/day and to respectively +1.9 
SDS and +0.5 SDS in children treated with 2 mg GH/m2/day (Sas et al., 1999).  
 
 
Fig. 5. Mean GH levels for each time point during an overnight GH profile before and after 6 
months of growth hormone treatment. Closed figures: 1 mg GH/m2/day, open figures: 2 
mg GH/m2/day (Van Dijk et al., 2006). 
At 6.5 years after discontinuation of growth hormone treatment, IGF-I and IGFBP-3 levels 
had returned to levels comparable with those found in untreated short subjects born SGA 
and thus significantly lower than levels found in controls (Van Dijk et al., 2007). 
5.3 Effects on insulin sensitivity, lipid profile and body composition 
Large surveillance databases have demonstrated that growth hormone treatment is well-
tolerated and adverse events are not more common in short SGA children than in other 
conditions that require growth hormone treatment (Cutfield et al., 2006). 
Monitoring of glucose and insulin levels during growth hormone treatment is necessary, 
because growth hormone has insulin-antagonistic effects. Prepubertal short SGA children 
develop a relative insulin resistance during growth hormone treatment, which is largely 
reversible when treatment is terminated. Six years after discontinuation, insulin sensitivity 
in short SGA children who were treated with growth hormone was similar compared to 
untreated short individuals born SGA (de Zegher et al., 2002; van Dijk et al., 2007). Growth 
hormone treatment has positive effects on lipid metabolism and blood pressure in 
prepubertal short SGA children and these effects persisted after discontinuation (Sas et al., 
2000; van Dijk et al., 2007). Growth hormone has well-documented anabolic effects on 
muscle mass and lipolytic effects on adipose tissue (Mukherjee et al., 2004). During 
treatment in prepubertal short SGA children, the increase in lean mass SDS adjusted for 
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gender and height reflected the normal increase as a result of the increase in height, without 
an additional anabolic effect. Fat mass SDS adjusted for gender and height declined in 
prepubertal SGA children, especially during the first treatment year (Willemsen et al., 2007).   
5.4 Effects on intellectual outcome and health-related quality of life 
During 9 yr of GH treatment, IQ and psychosocial functioning had improved from scores 
significantly below average to scores comparable to Dutch peers (Figure 6) (van Pareren et 
al., 2004). 
Health-related quality of life improves in growth hormone treated adolescents born SGA, 
according to the disorder-specific questionnaire which is designed to assess the impact of 
short stature on quality of life for children aged 5-15 years (The TNO AZL Children’s 
Quality of Life-short stature (TACQOL-S)). This improvement continued until adult height. 
Health-related quality of life was not different between individuals treated with 1 or 2 mg 
GH/m2/day (Bannink et al., 2010). Other studies did not find a significant improvement 
(Stephen et al., 2011). 
 
 
Fig. 6. Estimated total IQ score for both GH groups during growth hormone treatment, 
corrected for gender and age at start. Significant increase from start: *, P < 0.001 (van 
Pareren et al., 2004). 
6. Puberty in short children born small for gestational age 
Controversies exist about the relationship between being born SGA and reproductive 
function. In men born SGA, lower testosterone levels and smaller testicular size have been 
described (Cicognani et al., 2002). In women born SGA, smaller ovaries and uterus and 
lower anti-Mullerian hormone levels – a marker of follicle pool size – have been described 
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(Ibanez et al., 2003). These findings could not be replicated by others (Hernandez et al., 2006; 
Jensen et al., 2007). In a large cohort, it was recently shown that being born SGA does not 
have a negative effect on gonadal function in adult men. Factors that affect gonadal function 
are socio-economic status, fat mass, and maternal smoking during gestation, although all 
values of gonadal parameters remained within the normal range (Kerkhof et al., 2009). In 
women, being born SGA does not result in lower anti-Mullerian hormone levels. Catch-up 
growth after being born SGA might, however, be associated with increased anti-Mullerian 
hormone levels. Testosterone and androstenedione levels were comparable to levels in a 
control population. Other factors associated with serum anti-Mullerian hormone levels are 
oral contraceptive use, age at menarche, maternal smoking during gestation and socio-
economic status (Kerkhof et al., 2010).  
Growth hormone treatment has no detrimental effect on gonadal function in prepubertal 
short children born SGA (Boonstra et al., 2008; Lem et al., 2011). 
7. Postponement of puberty in pubertal short children born small for 
gestational age 
It has been indicated that a better growth response and greater adult height is achieved 
when children start growth hormone treatment at an early age (Carel et al., 2003). Although 
the age of onset and progression of puberty in short SGA children is comparable to healthy 
peers, some of these children only come under medical attention at onset of puberty. 
Postponement of puberty with gonadotropin releasing hormone analogue (GnRH analogue) 
is the treatment of choice in children with central precocious puberty or early puberty. Most 
of these children reach an adult height within their target height range (Mul et al., 2002; 
Palmert et al., 1999; Pasquino et al., 2008). It is yet unknown whether the same applies to 
short children bon SGA who come under medical attention at onset of puberty. 
7.1 Effects of GnRH analogue treatment on growth and the GH-IGF-IGFBP axis 
During GnRH analogue treatment, a decline in growth velocity – even to levels below the 
age-appropriate normal range in some patients – is a well-known phenomenon (Carel et al., 
1996; Saggese et al., 1993). Some studies in children with central precocious puberty found 
lower stimulated and spontaneous growth hormone levels during GnRH analogue 
treatment, others could not replicate these findings (DiMartino-Nardi et al., 1991; Sklar et al., 
1991; Stanhope et al., 1988). Poor growth might also be directly related to reduced sex 
steroid levels or growth plate senescence by prior estrogen exposure (Savendahl, 2005; 
Weise et al., 2004).   
In girls with normal stature, growth hormone secretion increases during puberty with the 
highest levels found at Tanner stage 3 and stage 4 (Rose et al., 1991). In contrast, pubertal 
short SGA girls have similar growth hormone levels compared to prepubertal short SGA 
girls (van der Kaay et al., 2009b). The lack of a rise in growth hormone levels during puberty 
in short SGA girls might play a role in the less intense pubertal growth spurt found in short 
SGA children who do not receive growth hormone treatment (Luo et al., 2003). 
Treatment with subcutaneous leuprorelide acetate depots of 3.75mg every 4 weeks results in 
adequate pubertal suppression in pubertal short SGA children (van der Kaay et al., 2009c; 
van der Kaay et al., 2009d).  
GnRH analogue treatment in pubertal short SGA girls results in a reduction of serum 
growth hormone levels, to levels lower than those found in prepubertal short SGA girls. The 
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interindividual variability in growth hormone secretion in response to a GnRH analogue is 
significant (Figure 7). One third of short SGA girls had a reduction in growth hormone 
levels of more than 40%. These girls also demonstrated a greater decrease in IGF-I and 
IGFBP-3 levels, compared to girls who showed a reduction in growth hormone levels 
between 0 and 40%. There is no association between growth hormone levels and estrogen 
levels, or between growth hormone levels and luteinizing hormone levels. This implies that 
girls with the same degree of pubertal suppression have different growth hormone 
responses during GnRH analogue treatment (van der Kaay et al., 2009b). 
 
 
Fig. 7. Mean growth hormone levels for each individual girl during an overnight growth 
hormone profile before (white bars) and after 3 months of GnRHa treatment (black bars) 
(van der Kaay et al., 2009b). 
7.2 Effects of GnRH analogue treatment on the metabolic profile 
Most of the studies performed in children with central precocious puberty have focused 
on adult height, bone mineral density and restoration of the reproductive system after 
long-term treatment with GnRH analogues. Much less attention has been paid to changes 
in body composition. Some studies report an increase in fat mass or BMI during GnRH 
analogue treatment, with a return to values comparable to those at baseline after 
discontinuation (Pasquino et al., 2008; van der Sluis et al., 2002), whereas others report no 
changes (Palmert et al., 1999) or even a decreased BMI during GnRH analogue treatment 
(Arrigo et al., 2004). Lean body mass SDS decreases during GnRH analogue treatment 
(van der Sluis et al., 2002). 
There is a physiological decrease in insulin sensitivity with pubertal progression (Hannon et 
al., 2006). Since both growth hormone and IGF-I levels significantly increase during puberty, 
the higher GH levels during puberty are thought to contribute to the pubertal insulin 
resistance (Moran et al., 2002). A brief period of GnRH analogue treatment in young, healthy 
women did not result in changes in insulin secretion (Toth et al., 2008). The effect of GnRH 
analogue treatment on insulin sensitivity in children with central precocious puberty is, 
however, unknown.  
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8. Combined treatment with a GnRH analogue and growth hormone in 
pubertal short children born small for gestational age  
Studies in patients with idiopathic growth hormone deficiency demonstrated a beneficial 
effect on adult height in favor of combined treatment with a GnRH analogue and growth 
hormone, compared to growth hormone treatment alone (Mericq et al., 2000; Saggese et al., 
2001). In children with idiopathic short stature contradictory results have been found (Lanes 
et al., 1998; Pasquino et al., 2000).  
8.1 Effects on the GH-IGF-IGFBP axis 
Similar to prepubertal short SGA children treated with either 1 or 2 mg GH/m2/day, pubertal 
short SGA children treated with a GnRH analogue and either 1 or 2 mg GH/m2/day show a 
dose-dependent increase in growth hormone levels (Figure 8). Growth hormone levels in 
pubertal short SGA children were, however, lower than levels in prepubertal short SGA 
children treated with a similar dose of growth hormone. Moreover, growth hormone levels in 
pubertal short SGA children treated with a GnRH analogue and 2 mg GH/m2/day were 
similar to growth hormone levels in prepubertal short SGA children treated with 1 mg 
GH/m2/day. Since growth hormone levels decrease during GnRH analogue treatment, these 
lower growth hormone levels might be the result of simultaneous treatment with a GnRH 
analogue, next to growth hormone (van der Kaay et al., 2010). Nevertheless, growth hormone 
levels in pubertal short SGA children treated with a GnRH analogue and 2 mg GH/m2/day 
remain elevated for a great part of the day. Similar to prepubertal short SGA children, there is 
a wide interindividual variation in growth hormone levels in response to either 1 or 2 mg 
 
 
Fig. 8. Mean growth hormone levels for each time point during an overnight growth hormone 
profile after 1 year of combined treatment with a GnRH analogue and growth hormone. Open 
squares: 1 mg GH/m2/day, solid squares: 2 mg GH/m2/day (van der Kaay et al., 2010). 
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GH/m2/day. Genetic variability in growth-related genes probably accounts for part of this 
variation, next to variations in physiological mechanisms involved in degradation of growth 
hormone at the site of injection and in the systemic circulation.  
Pubertal short SGA children treated with a GnRH analogue and either 1 or 2 mg 
GH/m2/day show a dose-dependent increase in IGF-I levels. Compared to the population 
mean, IGF-I levels are significantly lower at start of growth hormone treatment and 
significantly higher after 1 year of combined treatment. IGFBP-3 levels increase as well, but 
to a lesser extent than IGF-I levels. This results in an increase in levels of free, biologically 
active IGF-I which stimulates growth. Similar to prepubertal short SGA children treated 
with 2 mg GH/m2/day, a greater percentage of pubertal short SGA children treated with a 
GnRH analogue and 2 mg GH/m2/day have IGF-I SD scores in the highest quintile (> 0.84 
SDS), compared to children treated with a GnRH analogue and 1 mg GH/m2/day. 
Reassuringly, the percentage of children with IGF-I SD scores above +2 SDS was not 
different between both growth hormone dosage groups (van der Kaay et al., 2010). Concern 
has been expressed about the association between high IGF-I levels during several years and 
long-term cancer risk (Renehan et al., 2004). Although pubertal short SGA children will be 
treated with growth hormone for a relatively short period of time, it is important to monitor 
IGF-I levels during growth hormone treatment in order to titrate the growth hormone dose 
to IGF-I levels within the age-appropriate normal range. 
8.2 Effects on insulin sensitivity 
In pubertal short SGA children, insulin sensitivity (Si) – measured by frequently sampled 
intravenous glucose tolerance tests – is lower and insulin secretion (acute insulin response 
(AIR)) is higher, compared to prepubertal short SGA children. This was expected since 
pubertal children have a physiological decrease in insulin sensitivity.  
During combined treatment with a GnRH analogue and either 1 or 2 mg GH/m2/day, 
insulin sensitivity decreases and insulin secretion increases. The disposition index remained 
comparable to baseline, reflecting that β-cells are able to compensate for the reduction in 
insulin sensitivity by increasing their insulin secretion. Insulin sensitivity and secretion was 
comparable between children treated with either 1 or 2 mg GH/m2/day (Table 3) (van der 
Kaay et al., 2010). 
8.3 Effect on lipid profile and blood pressure 
In pubertal short SGA children, mean total cholesterol (TC), low density lipoprotein-
cholesterol (LDL-c), high density lipoprotein-cholesterol (HDL-c), triglycerides (TG), non-
esterified fatty acids (FFAs), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo B) and 
lipoprotein (a) (lp(a)) are within the normal range. Lipoprotein (a) levels are, however, above 
the normal range in 27% of pubertal short SGA children. High lipoprotein (a) levels have been 
associated with an increased risk of developing cardiovascular disease (Danesh et al., 2000).  
During combined treatment with a GnRH analogue and either 1 or 2 mg GH/m2/day, very 
small increases and/or decreases of lipid levels are found. The clinical significance of these 
small changes is considered negligible. Lipid levels are comparable between children treated 
with either 1 or 2 mg GH/m2/day (Table 3) (van der Kaay et al., 2010). 
Systolic blood pressure (BP) is higher in pubertal short SGA children than in controls and 
27% of pubertal short SGA children have a systolic blood pressure above + 2 SDS adjusted 
for gender and height. Higher blood pressure in childhood has been associated with an 
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increased risk of developing hypertension in adulthood. Systolic blood pressure does not 
change during 2 years of combined treatment with a GnRH analogue and either 1 or 2 mg 
GH/m2/day (Table 3). This is in line with previous findings, where a decrease in blood 
pressure was found only after 3 years of growth hormone treatment (Willemsen et al., 2008). 
 
 
ND = not determined; *P<0.0001 compared with the population mean (0 SDS); †P<0.03: 1 year of 
combined treatment, compared with the start of GnRH analogue treatment; ‡P<0.03: 3 months after the 
stop of GnRH analogue treatment, compared with the start of GnRH analogue treatment; §P<0.02: 3 
months after the stop of GnRH analogue treatment, compared with 1 year of combined treatment (van 
der Kaay et al., 2010). 
Table 3. Blood pressure, insulin sensitivity, and lipids at the start of GnRH analogue 
treatment, after 1 year of combined treatment and 3 months after the stop of GnRH 
analogue treatment in short SGA children with continuation of growth hormone treatment. 
Data are expressed as model estimate (95% CI), after adjustment for gender and Tanner 
stage at baseline. The values between brackets represent reference ranges for healthy 
children.   
8.4 Effects on body composition 
Fat mass adjusted for height and gender (SDSheight) in pubertal short SGA children is 
significantly lower than the population mean, consistent with findings in prepubertal short 
SGA children (Willemsen et al., 2007). During treatment with a GnRH analogue and 1 mg 
GH/m2/day, fat mass SDSheight significantly increases to values comparable to the population 
mean. In contrast, during 1 year of treatment with a GnRH analogue and 2 mg GH/m2/day, 
fat mass SDSheight decreases. During 2 years of combined treatment, fat mass SDSheight values 
return to those comparable before start of treatment – remaining significantly lower than the 
population mean in children treated with a GnRH analogue and 2 mg GH/m2/day (Figure 9). 
Although the percentage of trunk fat increases in pubertal short SGA children treated with 
GnRHa and either 1 or 2 mg GH/m2/day, values are lower in children treated with GnRHa 
and 2 mg GH/m2/day (Figure 9). This indicates that pubertal short SGA children develop 
relatively more fat mass around the waist, but that the increase is less when GnRH analogue 
treatment is combined with 2 mg GH/m2/day. In prepubertal short SGA children treated with 
2 mg GH/m2/day, percentage trunk fat remains comparable to untreated children. Thus, the 
increase in percentage trunk fat in pubertal short SGA children is most likely due to treatment 
with a GnRH analogue, next to growth hormone (van der Kaay et al., 2010). 
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Fig. 9. Changes in fat mass SDSheight and percentage trunk fat during 27 months of GnRH 
analogue and growth hormone treatment. Data are expressed as mean (± standard error of 
the mean (SEM)). Diamonds represent values during treatment with a GnRH analogue and 
1 mg GH/m2/day. Squares represent values during treatment with a GnRH analogue and 2 
mg GH/m2/day. Mean percentage trunk fat=(trunk fat/total trunk mass)x100. * P<0.01, # 
P<0.05 (van der Kaay et al., 2010). 
Several studies reported an increase in fat mass or BMI during GnRH analogue treatment in 
children with central precocious puberty. This might be explained by the lower growth 
hormone levels found during GnRH analogue treatment, as reported in children with growth 
hormone deficiency (Boot et al., 1997). Growth hormone has well-documented lipolytic effects 
and growth hormone treatment in prepubertal short SGA children results in a significant 
decrease in fat mass SDSheight, especially in the first treatment year. In pubertal short SGA 
children, treatment with 2 mg GH/m2/day counteracts the fat-accumulating effect of 
simultaneous treatment with a GnRH analogue, whereas treatment with 1 mg GH/m2/day is 
insufficient to prevent children from gaining fat mass during GnRH analogue treatment.   
Epidemiological studies have shown that low birth weight followed by catch-up in fat mass 
during childhood and adolescence is associated with a higher risk of developing type 2 
diabetes and cardiovascular disease, even when fat mass remains within the normal range. 
Follow-up until adult height is required to investigate the long-term effects of changes in 
body composition and metabolic profile in short SGA children treated with a combination of 
GnRH analogue and growth hormone. 
Lean body mass SDSheight in pubertal short SGA children is significantly lower than the 
population mean. It was previously shown that older prepubertal short SGA children have a 
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lower lean body mass SDSheight compared with younger prepubertal short children born 
SGA (Willemsen et al., 2007).  
During combined treatment with a GnRH analogue and either 1 or 2 mg GH/m2/day, lean 
body mass SDSheight increases only in pubertal short SGA children treated with a GnRH 
analogue and 2 mg GH/m2/day, although values remain significantly lower than the 
population mean. It is known that in children with central precocious puberty, lean body 
mass decreases during GnRH analogue treatment. Only combining 2 mg GH/m2/day with 
a GnRH analogue results in an increase in lean body mass SDSheight in older short SGA 
children (Figure 10) (van der Kaay et al., 2010).  
 
 
Fig. 10. Changes in lean body mass SDSheight during 27 months of GnRH analogue and 
growth hormone treatment. Data are expressed as mean (± standard error of the mean 
(SEM)). Diamonds represent values during treatment with a GnRH analogue and 1 mg 
GH/m2/day. Squares represent values during treatment with a GnRH analogue and 2 mg 
GH/m2/day. # P<0.05 (van der Kaay et al., 2010). 
9. General conclusions and practical implications 
Since growth hormone treatment was approved by the US Food and Drug Administration 
(FDA) in 2001 and by the European Agency for Evaluation of Medicinal Products (EMEA) in 
2003, short children born small for gestational age comprise a large group of growth 
hormone treated children.  
Various studies demonstrated that growth hormone treatment in prepubertal short SGA 
children effectively and safely induces catch-up growth. Better growth responses and 
greater adult height are achieved when children start growth hormone treatment at an 
early age. Some short SGA children, however, come under medical attention at onset of 
puberty.  
Pubertal short SGA girls lack the usual increase in growth hormone levels that accompanies 
the pubertal growth spurt, as found in pubertal girls with normal stature. Furthermore, 
GnRH analogue treatment results in a decrease in growth hormone levels to levels lower 
than those found in prepubertal short SGA girls. The lack of a rise in growth hormone levels 
during puberty in short SGA girls might play a role in the less intense pubertal growth spurt 
found in short SGA children who do not receive growth hormone treatment.  
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During combined treatment with a GnRH analogue and either 1 or 2 mg GH/m2/day, 
growth hormone and IGF-I levels show a dose-dependent increase, although growth 
hormone levels are lower compared to levels in prepubertal short SGA children treated with 
the same GH dose. Moreover, growth hormone levels in pubertal short SGA children 
treated with a GnRH analogue and 2 mg GH/m2/day are similar to growth hormone levels 
in prepubertal short SGA children treated with 1 mg GH/m2/day. During 2 years of 
combined treatment, the higher dose of 2 mg GH/m2/day has a favorable effect on fat mass 
SDS, percentage trunk fat and lean body mass SDS. Blood pressure, insulin sensitivity and 
lipid profile are similar between children treated with a GnRH analogue and 1 or 2 mg 
GH/m2/day. Combined treatment has no adverse effect on these metabolic parameters.  
Thus, combined treatment with a GnRH analogue and either 1 or 2 mg GH/m2/day – 
possibly in favor of treatment with a GnRH analogue and 2 mg GH/m2/day – can be 
considered as a safe treatment strategy in the short run for short children born small for 
gestational age who come under medical attention at onset of puberty. Adult height data 
need to be awaited before definitive conclusions can be drawn concerning the long-term 
efficacy and safety of this combined treatment.  
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